Scinopharm Taiwan (TPE:1789) Research & Development: NT$497 Mil (TTM As of Dec. 2025)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
76 GF Score
Price NT$20.00
GF Value NT$27.02
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Research & Development?

Scinopharm Taiwan TPE:1789 -2.68% 76 Research & Development is NT$497 Mil as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Scinopharm Taiwan's Research & Development for the three months ended in Dec. 2025 was NT$195 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$497 Mil.

Scinopharm Taiwan  (TPE:1789) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Scinopharm Taiwan Research & Development Related Terms

Scinopharm Taiwan Research & Development Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Research & Development Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 305.95 271.26 357.74 459.36 497.28

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 169.15 67.24 113.47 121.40 195.17
TPE:1789
76GF Score
Scinopharm Taiwan Ltd TPE:1789
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$497 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$497 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Research & Development of NT$497 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Research & Development too high?
Scinopharm Taiwan's current Research & Development is NT$497 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Research & Development compare to ZTS?
Scinopharm Taiwan's Research & Development of NT$497 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Research & Development is NT$497 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.00 — trading 26% below its estimated fair value. The current Research & Development is NT$497 Mil. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Research & Development is NT$497 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.00 is trading 26% below its estimated GF Value™ of NT$27.02. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Research & Development: NT$497 Mil
  • GF Value™: NT$27.02 vs. price of NT$20.00 (26% below fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score

Get the complete analysis for TPE:1789

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.00
Price
NT$27.02
GF Value